COVID-19 and Angiotensin-Converting Enzyme Inhibitor/Angiotensin-Receptor Blocker Therapy.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 32422077.
- Also identified by DOI 10.7326/M20-3047 and PMC identifier 7249506.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Mackey and colleagues reported a systematic review that found high-certainty evidence that angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers are not associated with greater illness severity in patients with COVID-19. The editorialist discusses the findings and emphasizes that, unless further data show otherwise, clinicians should continue to prescribe these drugs for their standard indications in patients with COVID-19.
Medical subject headings
- Angiotensin Receptor Antagonists
- Angiotensin-Converting Enzyme Inhibitors
- Coronavirus Infections
- Pandemics
- Pneumonia, Viral